Effects of cannabis use on outcomes of psychotic disorders: systematic review
Stanley Zammit, Theresa HM Moore, Anne Lingford‐hughes, Thomas R. E. Barnes, Peter Brian Jones, Margaret Burke, Glyn Lewis
The British Journal of Psychiatry October 31, 2008 DOI: 10.1192/bjp.bp.107.046375 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Systematic review Longitudinal Peer reviewed |
|---|---|
| Population | People with psychotic disorders, as examined in 13 longitudinal studies |
| Topics | Cannabis |
| Citations | 275 |
| Key findings | Cannabis use was consistently associated with increased relapse and non-adherence in people with psychotic disorders, but associations with other outcomes were more disparate. Because few studies adjusted for baseline illness severity, alcohol, or other confounders, and adjustment often substantially attenuated results, the authors conclude that confidence that most associations are specifically due to cannabis is low. |
Abstract
Background: It is unclear if research findings support clinical opinion that cannabis use leads to worse outcomes in people with psychosis, or whether this impression is confounded by other factors.
Aims: To systematically review the evidence pertaining to whether cannabis affects outcome of psychotic disorders.
Method: We searched 10 relevant databases (to November 2006), reference lists of included studies and contacted experts. We included 13 longitudinal studies from 15,303 references. Data extraction and quality assessment were conducted independently and in duplicate.
Results: Cannabis use was consistently associated with increased relapse and non-adherence. Associations with other outcome measures were more disparate. Few studies adjusted for baseline illness severity, and most made no adjustment for alcohol, or other potentially important confounders. Adjusting for even a few confounders often resulted in substantial attenuation of results.
Conclusions: Confidence that most associations reported were specifically due to cannabis is low. Despite clinical opinion, it remains important to establish whether cannabis is harmful, what outcomes are particularly susceptible, and how such effects are mediated. Studies to examine this further are eminently feasible.
Comparable studies
Other systematic reviews and meta-analyses on cannabis, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| The Impact of Cannabis Use on Cognitive Functioning in Patients With Schizophrenia: A Meta-analysis of Existing Findings and New Data in a First-Episode Sample Patients with established schizophrenia (meta-analysis: 572) and patients with... | 2010 | Meta-analysis and cross-sectional observational study | n = 700 |
| Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review | 2020 | Systematic review | |
| Neuroimaging in cannabis use: a systematic review of the literature Cannabis users and controls in neuroimaging studies | 2009 | Systematic review | |
| Human Laboratory Studies on Cannabinoids and Psychosis. Healthy human subjects and individuals with schizophrenia | 2016 | Systematic review | |
| Cannabis, a cause for anxiety? A critical appraisal of the anxiogenic and anxiolytic properties | 2020 | Systematic review |
Citations in the library
Cited by 42
- Medicinal cannabis for psychiatric disorders: a clinically-focused systematic review BMC Psychiatry January 16, 2020
- The Effect of Cannabis Use and Cognitive Reserve on Age at Onset and Psychosis Outcomes in First-Episode Schizophrenia Schizophrenia Bulletin March 9, 2011
- Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case–control study Psychological Medicine March 18, 2020
- Cannabis use and first-episode psychosis: relationship with manic and psychotic symptoms, and with age at presentation Psychological Medicine May 24, 2013
- Pathways from Cannabis to Psychosis: A Review of the Evidence Frontiers in Psychiatry 2013
and 37 more in the library
Cites 8
- The temporal dynamics of relationships between cannabis, psychosis and depression among young adults with psychotic disorders: findings from a 10-month prospective study. Psychological Medicine July 1, 2007
- Psychotic symptom and cannabis relapse in recent-onset psychosis The British Journal of Psychiatry August 1, 2006
- Cannabis use and outcome of recent onset psychosis European Psychiatry June 1, 2005
- Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biological Psychiatry March 15, 2005
- The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology August 2004
and 3 more in the library